Weekly Investment Analysts’ Ratings Changes for Intellia Therapeutics (NTLA)

A number of firms have modified their ratings and price targets on shares of Intellia Therapeutics (NASDAQ: NTLA) recently:

• 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $30.00 price target on the stock.
• 8/8/2026 – Intellia Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – Intellia Therapeutics was upgraded by Evercore Inc from “hold” to “outperform”. They now have a $24.00 price target on the stock.
• 7/17/2026 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Intellia Therapeutics was downgraded by Wolfe Research from “peer perform” to “underperform”. They now have a $9.00 price target on the stock.
• 7/10/2026 – Intellia Therapeutics had its price target raised by Wedbush from $12.00 to $17.00. They now have a “neutral” rating on the stock.

Insider Transactions at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by insiders.

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.